Stephen M. Ansell, MD, PhD and Andrew M. Evens, DO, MSc, FACP
In this episode, “Keeping Up with Hodgkin Lymphoma”, Stephen M. Ansell, MD, PhD and Andrew M. Evens, DO give us a snapshot of recent developments.
Management of classical Hodgkin lymphoma (cHL) has changed substantially over the past few years with approvals of several novel immunotherapies: brentuximab vedotin (BV) and the immune checkpoint inhibitors nivolumab and pembrolizumab. BV recently moved into frontline combination chemotherapy, having demonstrated improved PFS (especially in some patient subsets). Exciting results are now available with BV treatment in first relapse, either alone or in combinations. Roles for transplantation in cHL are also evolving.